Step 1:

         Step 2:

              Step 3:

ANDHealth+ Applications OPEN. Closing midnight 8 October 2021
ANDHealth+ is the leading digital health commercialisation program in Australia, with a proven track record of scaling digital health businesses across a broad range of clinical and commercial metrics.

ANDHealth+ is funded by the Australian Government under the Medical Research Future Fund Early Stage Translation and Commercialisation Support Program, with the intent of delivering a measurable impact on the selected SMEs’ ability to deliver new treatments or products to Australian patients, to undertake and provide access for more Australians to clinical trials, and to engage the clinician and patient community in embracing the potential of digital health and to the commercialisation and expansion of Australian digital health SMEs.

ANDHealth+ supports proof-of-concept stage, evidence-based digital health SMEs, which meet the MRFF definition of digital health as follows:

‘technologies that use computing platforms, connectivity, software and sensors, either alone or in combination with physical products, to treat,


diagnose, cure, mitigate and/or prevent disease or other conditions. Does not include digital health records, secure messaging, ePrescribing and other national digital health infrastructure.’ 

ANDHealth+ has a successful track record in taking businesses to scale, with the 10 companies selected in the pilot ANDHealth+ program raising over $70 million in funding, creating 296 jobs, undertaking 44 clinical studies and impacting over 200,000 patients in just four years.   

The program will open to applications annually with a new cohort selected each year on a competitive basis. SMEs who meet the eligibility criteria and complete the application requirements are assessed via a proven assessment and selection process, with five (up to a maximum of seven) SMEs selected each year. 

Selected SMEs will share in up to $3.75M of project funding per intake from the ANDHealth Digital Health Accelerator Fund alongside substantial in-kind services from pre-vetted suppliers and a dedicated ANDHealth support team providing hands-on support to undertake project activities, procure specialist expertise and meet agreed milestones.
Program Overview
ANDHealth+ is  not a grant program. ANDHealth+ is a commercialisation acceleration program,  in which participants work with ANDHealth and an industry team of experts to drive growth in their business, with two stages of project funding made  available through the ANDHealth Digital Health Accelerator Fund. 

Successful applicants will be selected via a  proven competitive process informed by a cross-section of multi-sectoral  industry leaders with experience in evaluating and selecting high potential  SMEs. Five SMEs will be selected each year (up to a maximum of seven in any  one year), from FY2022 to FY2025. 

Project engagements will run and be  supported by dedicated and specialised ANDHealth staff, enabling SMEs to  undertake pivotal activities such as clinical trials and real world commercial and clinical validation studies.  

With support from ANDHealth and  industry advisors, each SME will then prepare a project plan designed to  deliver maximum impact utilising a combination of cash and in-kind services  over two stages spanning 18 months. Key milestones  and go/no-go points will be defined within each stage.  

Funding and support will be provided to eligible activities that will significantly improve the applicant’s ability to commercialise, raise growth capital and/or execute on a market entry or growth strategy.
ANDHealth+ Projects
An Industry Advisory Panel (IAP) will be appointed for each cohort company, based on the specific requirements and optimal endpoints/outcomes for that SME with specific consideration given to ‘de-risking’ the company from the point of view of professional investors and enterprise customers.  

In consultation with their dedicated ANDHealth support team and IAP, selected SMEs will design two interrelated projects designed to accelerate their progress on the commercialisation pathway:

Stage 1 (Duration 3-4 Months):
Activities will focus on identifying key risks and addressing them using third-party expertise and the expertise of each company’s IAP.

Stage 2 (Duration 8-10 Months):
Activities will focus on achieving key clinical and commercial milestones which will drive institutional investment and/or enterprise customer uptake.
Benefits to Applicants
Direct access to the project funding, specialised expertise and ‘hands on’ resources needed to prove the clinical and commercial efficacy of your solution and accelerate your commercialisation, investment and growth outcomes.

✓ Multi-sectoral Industry Advisory Panel (IAP) of experts dedicated to your company.

Access to an International Investment AdvisoryCommittee (IIAC), comprising internationally recognised investors, clinicians, founders and executives from a diverse range of digital health businesses.

✓ Facilitated deal flow days with selected investors and customers (national and international) to inform stage 2 project plans and company growth strategy.

✓ Facilitated introductions to national and international networks of investors, global healthcare and technology companies and specialised service providers alongside participation in events, conferences and facilitated programs specific to evidence-based digital health companies.

Significant in-kind support from vetted suppliers, ANDHealth members and partners.

✓ Project management support from ANDHealth so that you can focus on your whole business while meeting the project milestones.

✓ No Equity Requirements: ANDHealth+ does not require any equity in consideration for participation.

✓ No Intellectual Property Transfer: ANDHealth does not assume any ownership of or require any royalties from intellectual property (IP) in the project.

✓ Cohort and Alumni only events, access to international experts, involvement in ANDHealth policy initiatives and promotion across the Australian healthcare landscape.
ANDHealth+ Alumni Case Studies
ANDHealth is extremely proud of the success experienced by our graduating cohort companies of FY2018 and FY2019. Their growth is indicative of the enormous untapped economic and healthcare impact potential of our nascent digital health sector.

Click on the links below to read about what our ANDHealth+ alumni has achieved.

Dose Me
AllergyPal
Atmo Biosciences
Perx
Seer Medical
SkinView
CancerAid
Health Delivered
Kesem Health
Vitalic Medical
How to Apply
• Read the instructions and information on the website: https://www.andhealth.com.au/our-programs/andhealth

•Register to attend an ANDHealth+ information session.

• After confirming your eligibility and attending the information session, book your 1-1 pre application consultation with the ANDHealth team here.
 
• Apply by submitting an application that addresses the eligibility and selection criteria and uploading all requisite attachments to the online application portal Gust : Apply here. 
• ANDHealth Lean Canvas template is available in Gust.  

• Letter of Board Support template is available in Gust.  

• Cohort Company Expectations document is available in Gust.  

• Submit your completed application with all accompanying attachments via the online application portaby  midnight AEST 8th October 2021.  
Entities must:

• Be an Australian SME i.e. a registered Australian corporate entity[1] employing no more than 199 employees[2] (SME) and be able to demonstrate that  they are authorised to use any IP required to perform the project

• Meet ASIC thresholds for small business including consolidated revenue of less than A$50M and/ or consolidated gross  assets of less than $25M at the end of the previous financial year[3]

• Have a minimum of one full-time employee engaged in the business. Preference will be given to applicants which can demonstrate sufficient management capacity and capability to effectively engage with the depth and breadth of the  ANDHealth+ program

• Have sufficient resources to service and complete the program and associated project plans  (operational runway, time, resources, headcount). It is important to note that ANDHealth+ allocated funds are applied to direct project costs only and not the day-to-day operations of the participant’s business.

• Will report on requisite outcomes data and other reporting metrics requested by ANDHealth as  required for three years beyond completion of the program.

Proposed  technologies and projects must:

• Meet the definition of “digital health” as outlined in the MRFF 2020 Early Stage Translation and Commercialisation Support Grant Opportunity  Guidelines i.e. ‘technologies that use computing platforms, connectivity,  software and sensors, either alone or in combination with physical products,  to treat, diagnose, cure, mitigate and/or prevent disease or other conditions. Does not include digital health records, secure messaging,  ePrescribing and other national digital health infrastructure.’

Involve a product/service/technology which has reached or substantially demonstrated  Proof of Concept/Proof of Principle

• Be evidence-based with a clear focus on improving patient outcomes.

Applicants must submit a fully completed application with all  requisite attachments/uploads.       

*Note: The ANDHealth+ Program has been  designed primarily for ‘for profit’ enterprises. Whilst non-profit  enterprises may be eligible to apply (assuming they meet other eligibility  criteria), they will need to clearly articulate how their participation in  ANDHealth+ will be ring-fenced from their ‘business as usual’ activities and  how impact of the program and any funded activities will be captured and  reported.
 

[1]  See https://asic.gov.au/for-business/small-business/#what  for Corporate Entity structures
[2]  MRFF 2020 Early Stage Translation and Commercialisation Support Grant  Opportunity Guidelines. Page 27
[3] https://asic.gov.au/for-business/small-business/#what    

Consideration will be given to:
• Extent to which the product delivers value through improved diagnosis, prevention, treatment, mitigation and/or management of chronic and acute conditions for the benefit of the patient.

Demonstrated understanding of the end user(s) and how they will interact with the product, including:
• Description of how the solution fits within clinical workflows and/or typical patient journeys.  
• Differentiation between the user(s), payers and beneficiaries  
• Evidence of Voice of User.

Uniqueness:
Clear articulation of competitive position and product advantage.

Maturity of the technology, including:
• Technical: evidence of proof of principle/concept use in the clinical or market setting is detailed; where applicable, access rights to key data required for operation are outlined (e.g. AI/ML training data).
• Strategy for patient data privacy and security.  
• Clinical: level of product evidence including clinical trials and technical certification.
• Regulatory: consideration of regulatory strategy including identification of TGA regulatory classification.  
• Traction: use of the product in a clinical or market setting.
• Scalability: consideration of barriers to scalability, such as required integrations, and extent of stakeholder identification and engagement.

Market and business case, including:
• Feasible business model.
• Articulation of value proposition to identified payers.  
• Evidence of market appetite, including Voice of Paying Customer evidence.  
• Size of market and pathway to market.  
• Intellectual property strategy and position.  
• Barriers to market entry.

Team, including:
• Business skills.
• Technical skills.  
• Track record and ability to achieve market uptake.  
• Diversity and inclusion: evident diversity in the advisory board, board, management team and a feasible strategy for maintaining/ achieving diversity.

Proposed Projects:
•Extent to which the proposed projects will positively affect clinical and commercial readiness of the project.

Preference will be given to companies who can demonstrate significant understanding of the complexity of the challenges of commercialisation of digital health.
All applications must be lodged through the online platform Gust, accessible here.

Before lodging your application, follow the steps below:


1. Interested applicants should register for an information session here.

2. Once eligibility is confirmed and you have read the information on the website and attended the information session, applicants are encouraged to book a pre-application consultation appointment here with an ANDHealth team member to discuss your proposed application and specific questions via the ANDHealth website, this will be released after the information session.

3. The application consists of application questions, a proposed project outline, and upload of four attachments:

   • Investor Pitch deck
   • ANDHealth Lean Canvas
   • 3-5 Year Financial Model
   • Letter of Board support (in the event that the applicant does not have a board, an option will       be made available for a letter from the CEO)
   • All applicants must articulate two projects (see ANDHealth+ Types of Projects tab) for which participation in the program will improve the likelihood of securing investment and/or substantially progress market entry.

4. To submit the application, applicants must also read and agree to the cohort company expectations document which is found on Gust.

5. Applications are assessed by the highly experienced ANDHealth team and ANDHealth Industry Selection Panel.

6. Top 10 applicants will undertake a 60 minute presentation and interview with the Industry Selection Panel.

7. The International Investment Advisory Committee (IIAC) will review and ratify the Industry Selection Panel’s recommendations for successful applicants.

8. Successful applicants will be notified. All unsuccessful applicants are provided with written feedback specific to their application.

Proposed Projects should focus on the development of clinical and/or commercial evidence to significantly improve the project’s ability to commercialise, raise growth capital and/or execute on a market entry or growth strategy.  

Two sequential projects will be supported with relevant milestones and go-no points defined within each.

Stage 1 (duration 3-4 months): 
Activities will focus on identifying key risks through a ‘working backwards’ model and, where possible, addressing them using third party expertise and the expertise of each company’s IAP. Outcomes of Stage 1 activities and the Stage 1 Investor & Customer Deal Flow Days will be used to inform Stage 2 project activities. 

Stage 2 (duration 8-10 months):
Activities will focus on achieving key clinical and commercial milestones which will drive institutional investment and/or enterprise customer uptake. Project activities will be focused on significant pieces of work which will have a clear and demonstrable impact on the growth trajectory of each cohort company.  

Note: Stage 2 projects will be subject to review by the IIAC and it is expected that some companies may not progress to stage 2.

Eligible activities include but are not limited to:

Product Development
• Product Verification and Validation  
•End-User Studies 
•UX/UI development to drive improved clinical outcomes 
• Intellectual property strategy 

Clinical Developments and Outcomes 
• Clinical Trial Planning and Protocol Design 
• Clinical Trial/Study Design and Execution 
• Clinical Trial Data Analytics 
• Efficacy in a clinical or industry setting 
• Voice of End-user(s) in clinical settings 
 
Manufacturing 
• Manufacturing assessments  
• Designfor Manufacture 
• Scaleup Manufacturing plans 

Commercial Strategy, Evidence and Outcomes 
• Go-to-Market Planning 
• Voice of Paying Customer Studies 
• Commercial Pilot Programs 
• Health Economics Assessments 
• Business Validation in End User Settings  
• International Market Strategy 
• Health Data and Independent Market Intelligence  
• Business and Financial Modelling 

Regulatory and Reimbursement  
• Independent Regulatory Strategy and Audits 
• Regulatory Certification or roadmap to certification (eg,TGA, FDA) 
• Reimbursement and Pricing Strategy, Verification and Audits 
• Cybersecurity  
• Data collection, storage, security and privacy  
• Quality Management Systems planning 
• Multi-jurisdictional compliance planning    

Ineligible activities include expenses not directly related to the projects approved within the ANDHealth+program. ‘Business as usual’ operations will not be supported. 

Ineligible activities include (but are not limited to): 

• General and administration costs for day-to-day business expenditure 
• Non-related staffing or contracting costs including the time commitment of applicant’s staff to supporting project activities 
• Ongoing software and hardware development 
• Marketing and branding costs 
• Fees paid to incentivise customers to use/ purchase your product or services  
• Costs of non-project specific travel and associated quarantine/ medical costs 
• Fees to government agencies such as ASIC.   

This is not a grant program. Project funds approved by the ADHAF are managed and paid directly to third-party suppliers by ANDHealth on behalf of successful applicants where possible. In certain situations, project funds may be paid to participating companies directly for expenditure on agreed outcomes. Participating companies will be required to provide verification of expenditure upon request by ANDHealth.  

Please note: Third-party activities supported by ANDHealth+ and financed by the ADHAF are carried out via a competitive tender. The tender process and contracting are supported by the applicant’s ANDHealth project support team. Within the application, applicants should focus on outlining the proposed activities and targeted outcomes, rather than including specific proposals from third-party providers.   

ANDHealth may determine that expenditure is ineligible and not directly related to the specific project at its discretion. 

Can I talk to someone about the program and my application
Yes. Once you have confirmed eligibility and attended or viewed a recording of the ANDHealth+ nformation ession, you can book a 30 minute meeting with the ANDHealth+ team to discuss your application.
Who is on the selection panel?
ANDHealth primarily utilises the expertise of its multi-sectoral members, alongside its extensive international digital health network, to ensure that all selection panels are comprised of C-Suite executives with proven expertise and demonstrable track records in commercialising digital health products and services.
When do I find out if I am shortlisted or successful?
We anticipate applicants will be advised if they have been successfully shortlisted by November 2021, with final outcomes advised prior to the end of December 2021.
What happens to the information I submit?
All information collected by ANDHealth programs is subject to the ANDHealth Data Collection Policy. Application specific information is treated as commercial in confidence.  All members of selection and advisory panels and committees operate under direct confidentiality agreements with ANDHealth.
What is the right stage for ANDHealth+? What is too early or too late?
Companies should have a working prototype, or ideally a product which is well progressed that have achieved proof of concept/proof of principle. Some customer traction or pilot activity should have been undertaken or in progress. Your company should have at least 1 FTE (with preference given to those with a full-time core team) and have the resources to complete the two stage project plan (operational runway, time, resources, headcount).
Who are the Industry Advisory Panel?  
The Industry Advisory Panel for each cohort company will be different and tailored for each cohort company according to their specific needs. ANDHealth is rigorous in their selection of panel members to ensure they consist only of individuals with a proven track record in their specialised area contributing to the commercialisation of digital health. All can demonstrate real-world experience in their area of expertise.
Who is the International Investment Advisory Committee (IIAC)  
The IIAC comprises internationally recognised investors, clinicians, founders and executives from a diverse range of digital health businesses. The IIAC  receive combined recommendations from selection panel and ANDHealth team and provide expert advice and input into project plans and investment amounts at both stages of the program.
Do you fund clinical trials?
The program will fund clinical and commercial studies where the endpoints articulated are considered to be highly relevant to the company’s successful commercialisation of its technology. “Types of Projects” link outlines the types of eligible projects activities that are expected be undertaken through ANDHealth+ based on prior experience.
What is the ANDHealth Digital Health Accelerator Fund (ADHAF)?
The ADHAF deploys the funding for the approved ANDHealth+ projects through a rigorous investment approval and governance process. All funding disseminated to applicants is subject to approval by the International Investment Advisory Committee and the ANDHealth Board.
When does my company receive the money?
This is not a grant program.  Most, if not all funds, will be issued to third party providers to deliver services on your behalf. The allocation of funds and the selection of providers will be done in consultation with your company, ANDHealth, and the Industry Advisory panel.  Any allocation of funds by the ADHAF will be subject to the approval of the ANDHealth Board.  ANDHealth+ does not fund ‘business as usual’ expenditure and applicants must ensure they have sufficient runway and resources to fully participate in the program.
Will there be more intakes of ANDHealth+?
There will be four intakes to the ANDHealth+ program in FY2022, FY2023, FY2024 and FY 2025 with 5 companies accepted into each intake (up to a maximum of seven per intake).
What is the IP policy for ANDHealth+?
ANDHealth was founded on a core principle of ensuring SME intellectual property remains solely under the ownership and control of each participating company.  ANDHealth and its members retain no legal rights, liens or rights of first refusal over any participating SME’s technology. Instead, we work closely with companies to both protect existing IP and create and protect new IP as a consequence of their participation in our programs. Companies accepted into ANDHealth+ execute an ANDHealth+ Participant Agreement. This agreement acknowledges that all SME background IP and Project IP flows to the participant company.
Cohort Company Outcomes (as at June 2021):
$42.7M
Raised (dilutive & non-dilutive)
$28.4M
New Revenue
296
New jobs (FTEs)
16
New CxO Roles
887
Commercial pilots commenced
44
Clinical trials and studies commenced
21
New international
market launches
217
New commercial customers
203,363
New patients served
425
New operational sites
58
New partnerships formed
153
New product releases
Testimonials
One of the key benefits of the ANDHealth+ program was that it was tailored to the needs of Vitalic Medical including our advisory panel. The advisory panel provided ongoing objective guidance on our business throughout the program helping to ensure we were focused in the right areas and on the right activities.
Sue Dafnias
CEO, Vitalic
The major difference I noted was the personalised nature to which the ANDHealth program is built. This ensured that we were not forced through standardised programs, expected to follow pre-ordained paths or work with professional generalists.
Charles Cornish
Executive Vice President, DoseMeRx (acquired by US-based Tabula Rasa HealthCare for up to AUD $40 million)
Digital health is an industry that often falls through the gaps between traditional software companies and biotech and the implications of this include lack of investor understanding, lack of commercialisation support and lack of industry expertise. ANDHealth goes a long way to solving these challenges by connecting digital health companies with leading stakeholders across all these groups and working to facilitate common understanding on how to work together.
Scott Taylor
CEO and Co-Founder, Perx Health
We have been part of numerous innovation communities including corporate incubators and VC-backed tech-accelerators. However, only ANDHealth+ has the deep expertise and commercial partnerships to truly understand a health-tech business and the unique hurdles they face to commercialise and find their path to market. Further, ANDHealth+ can be a trusted advisor with a clear mandate to help your business without competing interests.
Hugo Rourke
Co-Founder, Perx Health
ANDHealth provided Atmo with valuable digital health expertise and advice at a critical early-stage in the venture, which ultimately improved our ability to raise seed funding.
Malcom Hebblewhite
CEO, Atmo Biosciences
The ANDHealth team found the people and support we needed at the time we needed it. More than an accelerator, ANDHealth became an ongoing extension of my inner circle - a circle that helped me obtain a successful exit to a NASDAQ listed digital healthcare company.
Charles Cornish
Executive Vice President, DoseMeRx (acquired by US-based Tabula Rasa HealthCare for up to AUD $40 million)
The ANDHealth+ program was different to any other incubator and support we had received in the past. It was specific to the industry we were operating in - one that is particularly difficult to commercialise successfully in Australia - and our panel were experts. Blunt and honest in their feedback, they forced us to rethink our entire business model and value proposition.
Pete Saunders
Director, Health Delivered
The collective experience and resources brought by the program have enabled us to achieve pivotal milestones in commercialisation and clinical evidence generation and, as such, has enabled us to begin our global distribution, none of which would have been possible without our participation in the ANDHealth+ program.
Dr Raghav Murali-Ganesh
Co-Founder and President, CancerAid

Join our
mailing list

Stay up to date on news, programs and events
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.